Immune globulin - CSL Behring
Alternative Names: Beriglobin P; Berirab P; Carimune NF; Gamma Venin P; Hizentra; human immunoglobulin G; IgNextGen 10%; IgPro10; IgPro20; Immune Globulin Subcutaneous [Human] 20% Liquid; IVIG 10% -CSL Behring; Privigen; Redimune; Redimune NF; Rhesogamma P; Rhophylac; Sandoglobulin; Sandoglobulin NF; ScIG; Subcutaneous immunoglobulin; Tetagam P; Varicellon; Venimmun N; VivaglobinLatest Information Update: 05 Aug 2024
At a glance
- Originator CSL Behring
- Developer Assistance Publique Hopitaux de Paris; CSL Behring; Georgetown University; Rigshospitalet; University of Oxford
- Class Anti-infectives; Anti-inflammatories; Antibacterials; Antidementias; Antifibrotics; Antivirals; Eye disorder therapies; Immunoglobulins; Immunoproteins; Serum globulins; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Chronic inflammatory demyelinating polyradiculoneuropathy; Guillain-Barre syndrome; Haemolytic disease of newborn; Hepatitis A; Hepatitis B; Idiopathic thrombocytopenic purpura; Immunodeficiency disorders; Mucocutaneous lymph node syndrome; Rabies; Tetanus; Varicella zoster virus infections
- Phase III Dermatomyositis; Encephalitis; Renal transplant rejection
- Phase II Skin and soft tissue infections; Systemic scleroderma
- No development reported Lung transplant rejection; Motor neuron disease; Pelvic inflammatory disorders; Spinal cord injuries; Systemic lupus erythematosus
- Discontinued Diffuse scleroderma
Most Recent Events
- 02 Aug 2024 CSL Behring plans to initiate a phase III trial for Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) in the US (SC) (NCT06524739)
- 05 Jan 2024 9407050 - Updated KDM and completed FE. Drug already launched. Boxed warning already covered
- 31 May 2023 Adverse events and pharmacokinetics data from phase-II trial in Systemic Scleroderma presented at the 24th Annual Congress of the European League Against Rheumatism (EULAR-2023)